Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07806292 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study

Name: Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study — clinical trial record (NCT07806292)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ABH-uHCC

StatusRecruiting

PhasePhase 2

SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Started2025-04-28

View on ClinicalTrials.gov ↗

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

247 trials monitored

See 2 trials at risk

Liver Cancer

1,505 trials monitored

See 60 trials at risk

To evaluate the efficacy and safety of anlotinib combined with benmelstobart and HAIC as first-line treatment for unresectable hepatocellular carcinoma.

Trial Details

NCT Number	NCT07806292
Lead Sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions	Unresectable Hepatocellular Carcinoma
Enrollment	30 participants
Start Date	2025-04-28
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-04-28 (estimated)
Updated on ClinicalTrials.gov	2026-09-08